Methionine synthase polymorphism is a risk factor for Alzheimer disease

Katrin Beyer, José I. Lao, Pilar Latorre, Nadal Riutort, Belinda Matute, M. Teresa Fernández-Figueras, José L. Mate, Aurelio Ariza

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)

Abstract

Alzheimer disease (AD) patients show increased plasma levels of homocysteine, whose conversion to methionine is catalyzed by methionine synthase (MS). Although altered MS activity may result from the MS A2756G polymorphism, the latter's possible association with AD remains unexplored. To assess whether the MS A2756G polymorphism holds any influence on AD risk, we have analyzed 172 AD patients and 166 controls. We have also investigated whether the MS-A or MS-G allele interacts with the APOE4 allele. Our results indicate that association with the MS-AA genotype is an APOE4 allele-independent risk factor for AD. These findings provide novel evidence implicating genetic enzymatic alterations of homocysteine metabolic pathways in the pathogenesis of AD. © 2003 Lippincott Williams & Wilkins.
Original languageEnglish
Pages (from-to)1391-1394
JournalNeuroReport
Volume14
Issue number10
DOIs
Publication statusPublished - 18 Jul 2003

Keywords

  • Alzheimer disease
  • Homocysteine metabolism
  • Methionine synthase
  • Methionine synthase AA-genotype

Fingerprint Dive into the research topics of 'Methionine synthase polymorphism is a risk factor for Alzheimer disease'. Together they form a unique fingerprint.

  • Cite this

    Beyer, K., Lao, J. I., Latorre, P., Riutort, N., Matute, B., Fernández-Figueras, M. T., Mate, J. L., & Ariza, A. (2003). Methionine synthase polymorphism is a risk factor for Alzheimer disease. NeuroReport, 14(10), 1391-1394. https://doi.org/10.1097/00001756-200307180-00022